Abstracts tagged "ACE-inhibitors"

Abstract Number: 2077 • 2016 ACR/ARHP Annual Meeting
Impact of Diabetes, Angiotensin Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Use, and Statin Use on Presentation and Outcomes in Patients with Giant Cell Arteritis
Jocelyn Ma^1,2, Nader A. Khalidi³, Ola Wierzbicki², Abdallah Al Qethami⁴, Simon Carette⁵ and Christian Pagnoux⁶, ¹Department of Family Medicine, University of Toronto, Toronto, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³Division of Rheumatology, St. Joseph’s Health Care, McMaster University, Hamilton, ON, Canada, ⁴Internal Medicine/Adult Rheumatology, University of Toronto, Toronto, ON, Canada, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Few retrospective studies in giant cell arteritis (GCA) previously reported, separately, that 1) patients with diabetes had less positive temporal artery biopsies (TAB), 2)…
Abstract Number: 2716 • 2014 ACR/ARHP Annual Meeting
Development of a “Renal Crisis Prevention Card” As an Educational Tool Aimed at Improving Outcomes in High-Risk Patients with Systemic Sclerosis
Lee S. Shapiro^1,2,3, Lesley Ann Saketkoo⁴, Jessica F. Farrell^2,3,5 and Kim Fligelstone⁶, ¹Albany Medical College, Albany, NY, ²Steffens Scleroderma Center, Saratoga Springs, NY, ³The Center for Rheumatology, Albany, NY, ⁴Scleroderma and Sarcoidosis Patient Care and Research Center, Rheumatology and Pulmonary Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, ⁵Pharmacy Practice, Albany College of Pharmacy & Health Sciences, Albany, NY, ⁶Royal Free Hospital, Scleroderma Unit and Scleroderma Society, London, United Kingdom
Background/Purpose: Scleroderma renal crisis (SRC) is a devastating complication of SSc. The introduction of effective treatment with ACE inhibition (ACE-I) in 1979 dramatically reduced…
Abstract Number: 728 • 2012 ACR/ARHP Annual Meeting
Does the Use of Angiotensin Converting Enzyme Inhibitors Prior to Scleroderma Renal Crisis Affect Prognosis ? – Results of the International Scleroderma Renal Crisis Survey
Marie Hudson¹, Murray Baron², Solene Tatibouet¹, Daniel Furst³, Dinesh Khanna⁴ and International Scleroderma Renal Crisis Study Investigaots⁵, ¹Jewish General Hospital, McGill University, Montreal, QC, Canada, ²Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵Montreal
Background/Purpose: Scleroderma renal crisis (SRC) is an infrequent but life-threatening complication of systemic sclerosis (SSc). The outcome of SRC has improved considerably since the advent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].